Congenital Coagulopathies (Part II) Flashcards

1
Q

Causes VWF activity to rise

A

Physical stress such as cold, exertion, or a child’s cry- ing or struggling during venipuncture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

T/F: vWF activity rises when the phlebotomist allows the tourniquet to remain tied for more than 1 minute before venipuncture and descends if the specimen is stored in the refrigerator before testing.

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Concern over the poor reproducibility of results of the VWF:RCo assay has led to development of the

A

VWF collagen- binding (VWF:CB) assay.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Rheumatoid factor and heterophile antibodies interfere to cause

A

False positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Specimen mishandling such as prolonged tourniquet application, plasma refrigeration, filtration, or ultracentrifugation lead to

A

False positives, false negatives, or false phenotypes such as misidentifying a type 1 as a type 2 VWD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mild bleeding may resolve with the use of localized measures, such as

A

Limb elevation, pressure, and application of ice packs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

PRICE is an athlete’s acronym for

A

for protection, rest, ice, compression, and elevation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

May respond to estrogen and desmopressin acetate, which trigger the release of VWF from storage organelles

A

Moderate bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

is an antidiuretic hormone analog used to control incontinence in diabetes mellitus and bedwetting; release of VWF from storage organelles is a side effect

A

Desmopressin acetate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Is consistently effective for type 1 and subtype 2M VWD and generally useful for subtype 2A.

A

DDAVP, or oral spray form, Stimate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

inhibit fibrinolysis and may help control bleeding when used alone or in conjunction with desmopressin acetate.

A

Lysine analogs e-aminocaproic acid and tranexamic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

For treatment of severe VWD (type 3) and subtype 2B, three commercially prepared human plasma-derived high- purity preparations are available that provide a mixture of VWF and coagulation FVIII:

A

Humate-P, Alphanate, and Wilate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Essential to determine whether the given amount produced the target level of VWF and to follow its degradation between doses

A

VWF:Ag assay

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Is a recombinant VWF that provides no accompanying factor VIII.

A

Vonvendi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Are congenital single-factor deficiencies marked by anatomic soft tissue bleeding.

A

Hemophilias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Congenital deficiency of factor VIII is called

A

Classic hemophilia or hemophilia A.

16
Q

Is two-chain, 285,000-Dalton protein translated from the X chromosome.

A

Factor VIII

17
Q

When the coagulation cascade is activated, thrombin cleaves plasma FVIII and releases a large polypeptide called

18
Q

Sometimes called the tenase complex, cleaves and activates coagulation factor X at a rate 10,000 times faster than free factor IXa can cleave factor X

A

VIIIA/IXa complex

18
Q

Sometimes called the tenase complex, cleaves and activates coagulation factor X at a rate 10,000 times faster than free factor IXa can cleave factor X

A

VIIIA/IXa complex

19
Q

T/F: VIII deteriorates in storage. Donor blood collected in standard citrate-dextrose-phosphate preservative provides 30 units/dL FVIII activity after 28 days’ storage or approximately 50 units/dL in leukodepleted donor blood.

20
Q

Are exquisitely painful and cause temporary immobilization.

A

Acute joint bleeds

21
Q

Cause inflammation and eventual permanent loss of mobility, whereas bleeding into muscles may cause nerve compression injury, with first tempo- rary and then lasting disability

A

Chronic joint bleeds

21
Q

T/F: The severity of hemophilia A symptoms is inversely proportional to FVIII activity.

22
May transmit non-lipid viruses such as parvovirus B19 and hepatitis A virus
Human plasma-derived FVIII (pdFVIII)
23
contain VWF, fibrinogen, and noncoagulant proteins in addition to FVIII and are used to treat VWD
Alphanate, Humate-P, and Wilate
24
is used in many drug applications; it extends the rFVIII half-life to approximately 20 hours and reduces the infusion rate to approximately twice weekly.
PEGylation
25
Generate inhibitor titers of 5 NBUs or less and their inhibitor titers do not increase significantly after FVIII administration
Low responders
26
Generates inhibitor titers that exceed 5 NBUs ad their antibody titers
High responders
27
Often experience cessation of bleeding on administration of large doses of FVIII concentrate and may be so maintained
Low responders
28
May gain no benefit from FVIII concentrates and instead are treated with activated PCC (Auto-plex T or FEIBA), or rFVIIa (NovoSeven), all of which generate thrombin despite the presence of FVIII inhibitors
High responders
29
Is caused by deficiency of factor IX (FIX), one of the vitamin K-dependent serine proteases
Hemophilia B, also called Christmas disease
30
Is a substrate for both factors XIa and VIIa because it is cleaved by either to form dimeric factor IXa
Factor IX
31
Reduces thrombin production and causes soft tissue anatomic bleeding that is indistinguishable from that in hemophilia A.
Factor IX deficiency
32
Lab result for Hemophilia B: PTT: PT, TT, Fibrinogen:
PTT: Prolonged PT, TT and Fibrinogen: Normal
33
is a recombinant FIX concentrate (rFIX) grown in CHO cells in the absence of human or animal protein
BEnefix
34
An autosomal dominant hemophilia with mild to moderate bleeding symptoms.
Factor XI deficiency
35
T/F: The frequency and severity of bleeding episodes do not correlate with factor XI levels, and laboratory monitoring of treatment serves little pur- pose after the diagnosis is established
TRUE